J7209 HCPCS Level II code: Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.
J7209 is the HCPCS code for “Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7209Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.
Short description: Factor viii nuwiq recomb 1iu
HCPCS · United States
Medicare details
The indicators CMS publishes with J7209 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2017
Where J7209 sits
- 1J codesDrugs administered other than orally
- 2Active code J7209Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7209 mean?
J7209 is the HCPCS code for “Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7209?
CMS lists J7209’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7209
All J codesJ7202Injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u.J7203Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iuJ7204Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iuJ7205Injection, factor viii fc fusion protein (recombinant), per iuJ7207Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u.J7208Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.J7210Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u.J7211Injection, factor viii, (antihemophilic factor, recombinant), (kovaltry), 1 i.u.J7212Factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgramJ7213Injection, coagulation factor ix (recombinant), ixinity, 1 i.u.J7214Injection, factor viii/von willebrand factor complex, recombinant (altuviiio), per factor viii i.u.J7294Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each